Lates News

On May 14th, Novartis China announced that its breast cancer treatment product Kisqali (ribociclib succinate tablets) has been approved by the National Medical Products Administration for a new indication, to be used in combination with aromatase inhibitors as adjuvant therapy for early breast cancer patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative and high risk of recurrence. (Jiemian News)